Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
Abroad (travel likely)RecruitingPHASE1
Conditions
Healthy · Active Non-segmental Vitiligo · Severe Alopecia Areata
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality, China